Search results
Showing 76 to 90 of 219 results for chronic kidney disease
Question Frequency of monitoring: For adults, children and young people with CKD, what is the optimal monitoring frequency for...
Evidence-based recommendations on laparoscopic deroofing of simple renal cysts. This involves draining the cyst and removing part of the cyst wall through small cuts in the abdomen (keyhole surgery).
View recommendations for HTG145Show all sections
Sections for HTG145
Percutaneous transluminal renal sympathetic denervation for resistant hypertension (HTG662)
Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.
View recommendations for HTG662Show all sections
Implanting a baroreceptor stimulation device for resistant hypertension (HTG387)
Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.
criteria and shared care: What is the association between risk factors and CKD outcomes in children and young people? Any explanatory...
people with CKD? Any explanatory notes(if applicable) Source guidance details Comes from guidance Chronic kidney disease:...
Renin–angiotensin–aldosterone system antagonists: For people aged over 75 years with CKD, what is the clinical effectiveness of...
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.
Show all sections
Sections for NG256
- Overview
- Information and support
- Diagnosis
- Managing oncocytomas and Bosniak 2F cysts
- Managing localised and locally advanced renal cell carcinoma
- Managing advanced renal cell carcinoma
- Managing renal cell carcinoma in people with a heritable renal cell carcinoma predisposition syndrome
- Terms used in this guideline
Question Antiplatelet therapy: For people with CKD at the highest risk of cardiovascular disease, what is the clinical...
controlling serum phosphate in adults, children and young people with stage 4 or 5 CKD who are not on dialysis? Any explanatory notes(if...
with CKD? [2021] Any explanatory notes(if applicable) Source guidance details Comes from guidance Chronic kidney disease:...
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.
CKD–mineral and bone disorders: In people with hyperparathyroidism secondary to CKD, does treatment with vitamin D or vitamin D...
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with chronic kidney disease see our guideline on assessing and managing chronic kidney disease and for people with COVID-19 see our guideline on managing COVID-19.